Pan Pantziarka

2.3k total citations
47 papers, 1.5k citations indexed

About

Pan Pantziarka is a scholar working on Molecular Biology, Pulmonary and Respiratory Medicine and Oncology. According to data from OpenAlex, Pan Pantziarka has authored 47 papers receiving a total of 1.5k indexed citations (citations by other indexed papers that have themselves been cited), including 17 papers in Molecular Biology, 15 papers in Pulmonary and Respiratory Medicine and 13 papers in Oncology. Recurrent topics in Pan Pantziarka's work include Cancer Genomics and Diagnostics (7 papers), Computational Drug Discovery Methods (7 papers) and Cancer-related Molecular Pathways (6 papers). Pan Pantziarka is often cited by papers focused on Cancer Genomics and Diagnostics (7 papers), Computational Drug Discovery Methods (7 papers) and Cancer-related Molecular Pathways (6 papers). Pan Pantziarka collaborates with scholars based in Belgium, United Kingdom and Italy. Pan Pantziarka's co-authors include Gauthier Bouche, Vikas P. Sukhatme, Vidula Sukhatme, Lydie Meheus, Ciska Verbaanderd, Marco B.E. Schaaf, Patrizia Agostinis, Hannelore Maes, Praveen Vikas and Isabelle Huys and has published in prestigious journals such as The Lancet, Journal of Clinical Oncology and Annals of Oncology.

In The Last Decade

Pan Pantziarka

42 papers receiving 1.5k citations

Peers

Pan Pantziarka

ONCOL

CTM

PRM

Lydie Meheus Belgium

Vidula Sukhatme United States

Marc‐Eric Halatsch Germany

Janeen H. Trembley United States

Uma Yasothan United States

Zhitong Bing China

Chitra Subramanian United States

Richard Sedrani Switzerland

Moses M. Kasembeli United States

Sukyung Woo United States

Lydie Meheus Belgium

Pan Pantziarka

1.2k ×1.6

248 ×0.6

ONCOL

154 ×0.6

CTM

144 ×0.9

PRM

Citations per year, relative to Pan Pantziarka Pan Pantziarka (= 1×) peers Lydie Meheus

Countries citing papers authored by Pan Pantziarka

Since Specialization

Citations

This map shows the geographic impact of Pan Pantziarka's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Pan Pantziarka with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Pan Pantziarka more than expected).

Fields of papers citing papers by Pan Pantziarka

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Pan Pantziarka. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Pan Pantziarka. The network helps show where Pan Pantziarka may publish in the future.

Co-authorship network of co-authors of Pan Pantziarka

This figure shows the co-authorship network connecting the top 25 collaborators of Pan Pantziarka. A scholar is included among the top collaborators of Pan Pantziarka based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Pan Pantziarka. Pan Pantziarka is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Connolly, Elizabeth A., Kjetil Boye, Sylvie Bonvalot, et al.. (2025). Genetic predisposition in sarcomas: clinical implications and management. EClinicalMedicine. 83. 103203–103203.

Felix, A., Mehdi Brahmi, Nathalie Gaspar, et al.. (2025). Recurrent and Refractory Ewing Sarcoma Phase I/II Trials: Current Perspective From the Euro-Ewing Consortium. JCO Precision Oncology. 9(9). e2500377–e2500377.

Baldi, Giacomo Giulio, et al.. (2024). The patient perspective on sirolimus for epithelioid hemangioendothelioma (EHE): results of a community survey highlighting the importance of equitable access to treatments. Frontiers in Oncology. 14. 1367237–1367237. 1 indexed citations

Shaw, Rachel, Linda M. Collins, Pan Pantziarka, et al.. (2024). Cancer Precision-Prevention trial of Metformin in adults with Li Fraumeni syndrome (MILI) undergoing yearly MRI surveillance: a randomised controlled trial protocol. Trials. 25(1). 103–103. 5 indexed citations

Pantziarka, Pan, et al.. (2023). Drug evidence watch: a process to the benefit of public health. The Lancet. 402(10406). 945–947. 1 indexed citations

Pantziarka, Pan, et al.. (2023). Exploiting the Stemness and Chemoresistance Transcriptome of Ewing Sarcoma to Identify Candidate Therapeutic Targets and Drug-Repurposing Candidates. Cancers. 15(3). 769–769. 2 indexed citations

Lüke, Florian, Dennis Christoph Harrer, Pan Pantziarka, et al.. (2022). Drug Repurposing by Tumor Tissue Editing. Frontiers in Oncology. 12. 900985–900985. 7 indexed citations

Pantziarka, Pan, et al.. (2021). Repurposing Infectious Diseases Vaccines Against Cancer. Frontiers in Oncology. 11. 688755–688755. 18 indexed citations

Donnini, Sandra, et al.. (2020). Repurposing of drugs for triple negative breast cancer: an overview. ecancermedicalscience. 14. 1071–1071. 15 indexed citations

10.

Heudobler, Daniel, Florian Lüke, Martin Vogelhuber, et al.. (2019). Anakoinosis: Correcting Aberrant Homeostasis of Cancer Tissue—Going Beyond Apoptosis Induction. Frontiers in Oncology. 9. 1408–1408. 15 indexed citations

11.

Pantziarka, Pan, Lina Ghibelli, & Albrecht Reichle. (2019). A Computational Model of Tumor Growth and Anakoinosis. Frontiers in Pharmacology. 10. 287–287. 8 indexed citations

12.

Pantziarka, Pan, Ciska Verbaanderd, Vidula Sukhatme, et al.. (2018). ReDO_DB: the repurposing drugs in oncology database. ecancermedicalscience. 12. 886–886. 99 indexed citations

13.

Verbaanderd, Ciska, Hannelore Maes, Marco B.E. Schaaf, et al.. (2017). Repurposing Drugs in Oncology (ReDO)—chloroquine and hydroxychloroquine as anti-cancer agents. ecancermedicalscience. 11. 781–781. 203 indexed citations

14.

Kumar, Sanjeev, Linda Jones, W. Qian, et al.. (2017). PIONEER- Pre-operative wIndOw study of letrozole plus PR agonist megestrol acetate versus letrozole aloNE in post-menopausal patients with ER-positive breast cancer. Annals of Oncology. 28. v65–v66. 1 indexed citations

15.

Pantziarka, Pan. (2017). Scientific advice — is drug repurposing missing a trick?. Nature Reviews Clinical Oncology. 14(8). 455–456. 26 indexed citations

16.

Gyawali, Bishal, Pan Pantziarka, Lydie Meheus, & Gauthier Bouche. (2017). Repurposing non-cancer drugs in oncology: Aspirin and metformin are only the tip of the iceberg. Annals of Oncology. 28. x40–x40. 1 indexed citations

17.

Pantziarka, Pan, et al.. (2016). ecancermedicalscience. ecancermedicalscience. 8. ed40–ed40. 11 indexed citations

18.

Pantziarka, Pan, Gauthier Bouche, Lydie Meheus, et al.. (2016). ecancermedicalscience. ecancermedicalscience. 8. 442–442. 145 indexed citations

19.

Augustin, Yolanda, Sanjeev Krishna, Devinder Kumar, & Pan Pantziarka. (2015). The wisdom of crowds and the repurposing of artesunate as an anticancer drug. ecancermedicalscience. 9. ed50–ed50. 26 indexed citations

20.

Pantziarka, Pan. (2015). Primed for cancer: Li Fraumeni Syndrome and the pre-cancerous niche. ecancermedicalscience. 9. 541–541. 13 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact